Artera Funding, Investors & Competitors

Artera has raised $110M across 2 funding rounds, most recently a $20M undisclosed-stage round in February 2024.

Last Artera funding round

$20M

Undisclosed stage · Feb 2024

Cumulative funding Artera raised

$110M

across 2 funding rounds

Key investors in Artera

  • Walden Catalyst
  • Coatue
  • Johnson & Johnson Innovation
  • Breyer Capital
  • EDBI
  • Marc Benioff
  • Koch Disruptive Technologies
  • Prosperity7 Ventures

Artera Overview

About Artera

Artera is a Boston-based medical AI company developing software tests that analyze H&E histopathology images to predict cancer therapy responses and patient prognoses. Its platform integrates into routine clinical workflows, providing oncologists with personalized treatment insights without additional hardware. FDA-cleared for prostate and breast cancer applications, Artera collaborates with pathology labs and hospitals across the US and Europe. Founded in 2019, the company has validated its algorithms on datasets from over 10,000 patients, partnering with AstraZeneca for clinical trials.


Founded

2021

HQ

United StatesSan Francisco, CA

Website

artera.ai

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Artera Funding History

Artera has raised a total of $110M across 2 funding rounds.

Artera's first fundraising round was a $90M undisclosed-stage round in March 2023. The most recent completed round was a $20M undisclosed-stage round in February 2024.

Artera funding rounds

Artera funding rounds
DateStageInvestorsRaisedDeal Summary
Feb 2024Undisclosed stageNavin Chaddha; Andrew Tan; Prosperity7 Ventures; EDBI; Rajiv Khemani; Walden Catalyst; AIspace Ventures; Wilson Sonsini Goodrich & Rosati$20M-
Mar 2023Undisclosed stageBreyer Capital; Amarjit Gill; Clarence So; Koch Disruptive Technologies; Coatue; Breyer Labs; Marc Benioff; Walden Catalyst; Chris Re; Johnson & Johnson Innovation; Dennis Wong$90MArtera is a San Francisco-based precision medicine company developing multimodal artificial intelligence-based predictive and prognostic cancer tests to personalize therapy for cancer patients. The company was founded in late 2021 and launched publicly in March 2023 with its flagship ArteraAI Prostate Test, the first test to predict therapy benefits in localized prostate cancer. The test combines digital pathology and clinical data to deliver individualized treatment recommendations and is clinically available through a CLIA-certified laboratory in Jacksonville, Florida. Artera raised $90 million in Series A funding in March 2023 from a syndicate of prominent tech and healthcare investors including institutional investors Coatue, Johnson & Johnson Innovation (JJDC Inc.), Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, and The Factory, alongside 11 angel investors including Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, and Michael Driscoll. The company stated it had steered clear of Silicon Valley Bank and was in a healthy financial position focused on capital efficiency. The funding announcement came on the heels of Artera's positive data from ASCO GU 2023, demonstrating that the prognostic biomarker was validated across six phase III randomized trials, showing the multimodal AI biomarker's ability to enable personalized, shared decision-making for patients and clinicians. The fresh capital was earmarked to finance commercial distribution of the prostate cancer test in the United States and globally, as well as to develop tests supporting therapy personalization for other cancer types. Following the initial round, Artera raised an additional $20 million in Series B funding in February 2024 backed by Prosperity7 Ventures, bringing total capital raised to $110 million by that date.

Who has invested in Artera?

18 investors have backed Artera across its funding rounds, including Walden Catalyst, Coatue, Johnson & Johnson Innovation, Breyer Capital, EDBI and Marc Benioff.


Artera Investors

Investors in Artera by funding rounds participated
InvestorHQRoundsRoleFirst check
Walden CatalystUnited StatesSan Francisco, CA2ParticipantMar 2023
Navin ChaddhaUnited StatesSan Francisco, CA1ParticipantFeb 2024
Breyer CapitalUnited StatesSan Francisco, CA1ParticipantMar 2023
Andrew TanUnited StatesUnited States1ParticipantFeb 2024
Amarjit GillUnited StatesUnited States1ParticipantMar 2023
Clarence SoUnited StatesSan Francisco, CA1ParticipantMar 2023
Prosperity7 VenturesSaudi ArabiaDammam1ParticipantFeb 2024
Koch Disruptive TechnologiesUnited StatesWichita, KS1ParticipantMar 2023
EDBISingaporeSingapore1ParticipantFeb 2024
Rajiv KhemaniUnited StatesSan Francisco, CA1ParticipantFeb 2024
CoatueUnited StatesNew York City, NY1ParticipantMar 2023
Breyer LabsUnited StatesSan Francisco, CA1ParticipantMar 2023
Marc BenioffUnited StatesSan Francisco, CA1ParticipantMar 2023

This data is available for Pro users. Sign up to see all 18 Artera investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Artera Competitors

Artera competitors include listed companies like GE HealthCare, Pro Medicus and United Imaging, and private ones like ConcertAI, United Imaging Intelligence and Viz.

Public and private companies comparable to Artera
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
ConcertAIUnited StatesUnited StatesPrivate$200M-$1.9B9.5x
GE HealthCareUnited StatesUnited StatesPublicly listed$21B$3.7B$29B1.8x
Pro MedicusAustraliaAustraliaPublicly listed$186M$147M$13B62.7x
United ImagingChinaChinaPublicly listed$2.1B$367M$12B4.8x
United Imaging IntelligenceChinaShanghaiPrivate--$1.4B-
VizUnited StatesUnited StatesPrivate$100M-$1.3B12.8x

Artera Public Comps

Artera is still privately-owned, but its public comps include CrowdStrike, SAP, Salesforce, ServiceNow, Adobe, Datadog, Moody's, Natera, Workday and IQVIA.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x
SAP$42B$13B5.8x5.4x18.4x17.1x
Salesforce$42B$13B5.5x5.2x17.8x12.2x
ServiceNow$13B$2.6B11.1x9.6x57.2x25.0x
Adobe$24B$9.3B4.3x3.9x10.9x8.2x
Datadog$3.4B($588K)23.6x19.4x(137813.0x)77.6x
Moody's$7.7B$3.8B11.2x10.6x22.5x20.1x
Natera$2.3B($266M)22.5x19.0x(195.0x)(261.5x)

This data is available for Pro users. Sign up to see all Artera competitors and their valuation data.

Start Free Trial

Common questions about Artera

When was Artera founded?Artera was founded in 2021.
Where is Artera headquartered?Artera is headquartered in San Francisco, CA, United States.
Is Artera publicly listed?No, Artera is a private, VC-backed company.
How much funding has Artera raised?Artera has raised $110M across 2 funding rounds.
What was Artera's last funding round?Artera's last funding round was a $20M undisclosed-stage round in February 2024.
Who are Artera's investors?Artera's investors include Walden Catalyst, Navin Chaddha, Breyer Capital, Andrew Tan, Amarjit Gill, Clarence So, Prosperity7 Ventures, Koch Disruptive Technologies, EDBI, Rajiv Khemani and 8 others.
Which companies are comparable to Artera?Companies comparable to Artera include ConcertAI, GE HealthCare, Pro Medicus, United Imaging, United Imaging Intelligence and Viz.

See companies similar to Artera

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial